Open AccessClinical guidelines for cryoprecipitate transfusions
Author(s) -
Г М Галстян,
Т. В. Гапонова,
Е Б Жибурт,
E.N. Balashova,
А. Л. Берковский,
Быстрых Оксана Анатольевна,
А.А. Купряшов,
Н. И. Оловникова,
А В Ошоров,
М.М. Рыбка,
В В Троицкая,
А. Ю. Буланов,
S. V. Zhuravel,
А. Ю. Лубнин,
В.А. Мазурок,
С. В. Недомолкин,
Д. Э. Певцов,
О. В. Рогачевский,
Э. Л. Салимов,
Pavel Trakhtman,
А. В. Чжао,
Ф. С. Шерстнев,
В Г Савченко
Publication year - 2020
Publication title -
gematologiâ i transfuziologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-3042
pISSN - 0234-5730
DOI - 10.35754/0234-5730-2020-65-1-87-114
Subject(s) - cryoprecipitate , medicine , fresh frozen plasma , von willebrand factor , von willebrand disease , surgery , coagulation , neonatology , fibrinogen , platelet , pregnancy , biology , genetics
Background . Cryoprecipitate is made from fresh-frozen plasma (FFP) and contains brinogen, factor VIII, factor XIII, von Willebrand factor, bronectin and brinogen. Aim . To provide information on the composition and methods of production, storage, transportation and clinical use of cryoprecipitate. General ndings . Cyoprecipitate is manufactured by slowly thawing FFP at 1–6°C. This precipitates out cryoproteins: factor VIII, von Willebrand factor, factor XIII, bronectin and brinogen. After centrifugation, the cryoproteins are resuspended in a reduced volume of plasma. Cryoprecipitate is stored at temperatures not exceeding –25° С for 36 months. Indications for cryoprecipitate transfusion are hemophilia A, von Willebrand disease, factor XIII deciency, congenital abrinogenemia and hypobrinogenemia, acquired hypobrinogenemia. These indications can occur in obstetrics, neonatology, cardiac surgery, neurosurgery, hematology, orthopaedics, and general surgery during liver transplantation and disseminated intravascular coagulation.